{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:49:05Z","timestamp":1752230945308},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,8,15]],"date-time":"2014-08-15T00:00:00Z","timestamp":1408060800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s11940-014-0313-6","type":"journal-article","created":{"date-parts":[[2014,8,14]],"date-time":"2014-08-14T02:53:11Z","timestamp":1407984791000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment and Management of Neuromuscular Channelopathies"],"prefix":"10.1007","volume":"16","author":[{"given":"Lydia","family":"Sharp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaya R.","family":"Trivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,15]]},"reference":[{"key":"313_CR1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0960-8966(91)90039-U","volume":"1","author":"AE Emery","year":"1991","unstructured":"Emery AE. Population frequencies of inherited neuromuscular diseases\u2013a world survey. Neuromuscul Disord. 1991;1:19\u201329.","journal-title":"Neuromuscul Disord"},{"key":"313_CR2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02043311","volume":"3","author":"L Pinessi","year":"1982","unstructured":"Pinessi L, Bergamini L, Cantello R, et al. Myotonia congenita and myotonic dystrophy: descriptive epidemiological investigation in Turin, Italy (1955-1979). Ital J Neurol Sci. 1982;3:207\u201310.","journal-title":"Ital J Neurol Sci"},{"key":"313_CR3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.neuro.29.051605.112815","volume":"29","author":"SC Cannon","year":"2006","unstructured":"Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci. 2006;29:387\u2013415.","journal-title":"Annu Rev Neurosci"},{"key":"313_CR4","first-page":"3265","volume":"130","author":"D Fialho","year":"2007","unstructured":"Fialho D, Schorge S, Pucovska U, et al. Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain (Oxford University Press). 2007;130:3265\u201374.","journal-title":"Brain (Oxford University Press)"},{"key":"313_CR5","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1001\/archneur.1993.00540110101010","volume":"50","author":"EP Hoffman","year":"1993","unstructured":"Hoffman EP, Wang J. Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products. Arch Neurol. 1993;50:1227\u201337.","journal-title":"Arch Neurol"},{"key":"313_CR6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1071-9091(96)80041-6","volume":"3","author":"F Lehmann-Horn","year":"1996","unstructured":"Lehmann-Horn F, R\u00fcdel R. Channelopathies: the nondystrophic myotonias and periodic paralyses. Semin Pediatr Neurol. 1996;3:122\u201339.","journal-title":"Semin Pediatr Neurol"},{"key":"313_CR7","first-page":"851","volume":"49","author":"LJ Pt\u00e1cek","year":"1991","unstructured":"Pt\u00e1cek LJ, Trimmer JS, Agnew WS, et al. Paramyotonia congenita and hyperkalemic periodic paralysis map to the same sodium-channel gene locus. Am J Hum Genet. 1991;49:851\u20134.","journal-title":"Am J Hum Genet"},{"key":"313_CR8","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/sj.ejhg.5200736","volume":"9","author":"C Sun","year":"2001","unstructured":"Sun C, Tranebjaerg L, Torbergsen T, et al. Spectrum of CLCN1 mutations in patients with myotonia congenita in Northern Scandinavia. Eur J Hum Genet. 2001;9:903\u20139.","journal-title":"Eur J Hum Genet"},{"key":"313_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0065-2660(08)01001-8","volume":"63","author":"B Fontaine","year":"2008","unstructured":"Fontaine B. Periodic paralysis. Adv Genet (Elsevier). 2008;63:3\u201323.","journal-title":"Adv Genet (Elsevier)"},{"key":"313_CR10","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1212\/01.WNL.0000143383.91137.00","volume":"63","author":"TM Miller","year":"2004","unstructured":"Miller TM, Dias da Silva MR, Miller HA, et al. Correlating phenotype and genotype in the periodic paralyses. Neurology. 2004;63:1647\u201355.","journal-title":"Neurology"},{"key":"313_CR11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/brain\/awh639","volume":"129","author":"SL Venance","year":"2006","unstructured":"Venance SL, Cannon SC, Fialho D, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain. 2006;129:8\u201317.","journal-title":"Brain"},{"key":"313_CR12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ana.20241","volume":"56","author":"E Fournier","year":"2004","unstructured":"Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56:650\u201361.","journal-title":"Ann Neurol"},{"key":"313_CR13","first-page":"2189","volume":"136","author":"JR Trivedi","year":"2013","unstructured":"Trivedi JR, Bundy B, Statland J, et al. Non-dystrophic myotonia: prospective study of objective and patient reported outcomes. Brain (Oxford University Press). 2013;136:2189\u2013200. This is the largest non-dystrophic myotonia study describing genotype phenotype correlation and outcome measures for clinical trials.","journal-title":"Brain (Oxford University Press)"},{"key":"313_CR14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/mus.23320","volume":"46","author":"MR Rose","year":"2012","unstructured":"Rose MR, Sadjadi R, Weinman J, et al. Role of disease severity, illness perceptions, and mood on quality of life in muscle disease. Muscle Nerve. 2012;46:351\u20139.","journal-title":"Muscle Nerve"},{"key":"313_CR15","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1111\/j.1468-1331.2012.03751.x","volume":"19","author":"VA Sansone","year":"2012","unstructured":"Sansone VA, Ricci C, Montanari M, et al. Measuring quality of life impairment in skeletal muscle channelopathies. Eur J Neurol. 2012;19:1470\u20136.","journal-title":"Eur J Neurol"},{"key":"313_CR16","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1001\/jama.2012.12607","volume":"308","author":"JM Statland","year":"2012","unstructured":"Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA (American Medical Association). 2012;308:1357\u201365. This is the only randomized controlled trial ever performed in the non-dystrophic myotonias.","journal-title":"JAMA (American Medical Association)"},{"key":"313_CR17","doi-asserted-by":"crossref","unstructured":"Trip J, Drost G, van Engelen BGM, et al. Drug treatment for myotonia. Cochrane Database Syst Rev (Chichester, UK: John Wiley & Sons, Ltd) 2006;CD004762.","DOI":"10.1002\/14651858.CD004762.pub2"},{"key":"313_CR18","volume-title":"Goodman & Gilman's the pharmacological basis of therapeutics","author":"L Brunton","year":"2005","unstructured":"Brunton L, Lazo J, Parker K. Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw Hill Professional; 2005."},{"key":"313_CR19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/brain\/82.1.81","volume":"82","author":"P Leyburn","year":"1959","unstructured":"Leyburn P, Walton JN. The treatment of myotonia: a controlled clinical trial. Brain. 1959;82:81\u201391.","journal-title":"Brain"},{"key":"313_CR20","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1212\/WNL.17.4.359","volume":"17","author":"TL Munsat","year":"1967","unstructured":"Munsat TL. Therapy of myotonia. A double-blind evaluation of diphenylhydantoin, procainamide, and placebo. Neurology. 1967;17:359\u201367.","journal-title":"Neurology"},{"key":"313_CR21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0404.1992.tb05103.x","volume":"86","author":"H Kwieci\u0144ski","year":"1992","unstructured":"Kwieci\u0144ski H, Ryniewicz B, Ostrzycki A. Treatment of myotonia with antiarrhythmic drugs. Acta Neurol Scand. 1992;86:371\u20135.","journal-title":"Acta Neurol Scand"},{"key":"313_CR22","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s00228-012-1414-3","volume":"69","author":"J-F Desaphy","year":"2013","unstructured":"Desaphy J-F, Modoni A, Lomonaco M, et al. Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy. Eur J Clin Pharmacol (Springer-Verlag). 2013;69:1037\u20139.","journal-title":"Eur J Clin Pharmacol (Springer-Verlag)"},{"key":"313_CR23","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/(SICI)1097-4598(200001)23:1<138::AID-MUS23>3.0.CO;2-4","volume":"23","author":"A Berardinelli","year":"2000","unstructured":"Berardinelli A, Gorni K, Orcesi S. Response to carbamazepine of recessive-type myotonia congenita. Muscle Nerve. 2000;23:138\u20139.","journal-title":"Muscle Nerve"},{"key":"313_CR24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF02758569","volume":"73","author":"MR Savitha","year":"2006","unstructured":"Savitha MR, Krishnamurthy B, Hyderi A, et al. Myotonia congenita\u2013a successful response to carbamazepine. Indian J Pediatr. 2006;73:431\u20133.","journal-title":"Indian J Pediatr"},{"key":"313_CR25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.pediatrneurol.2010.01.014","volume":"42","author":"MJ Lyons","year":"2010","unstructured":"Lyons MJ, Duron R, Molinero I, et al. Novel CLCN1 mutation in carbamazepine-responsive myotonia congenita. Pediatr Neurol. 2010;42:365\u20138.","journal-title":"Pediatr Neurol"},{"key":"313_CR26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMcp0801738","volume":"359","author":"JA French","year":"2008","unstructured":"French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med. 2008;359:166\u201376.","journal-title":"N Engl J Med"},{"key":"313_CR27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.37.3.488","volume":"37","author":"RG Trudell","year":"1987","unstructured":"Trudell RG, Kaiser KK, Griggs RC. Acetazolamide-responsive myotonia congenita. Neurology. 1987;37:488\u201391.","journal-title":"Neurology"},{"key":"313_CR28","first-page":"292","volume":"34","author":"H Eguchi","year":"2006","unstructured":"Eguchi H, Tsujino A, Kaibara M, et al. Acetazolamide acts directly on the human skeletal muscle chloride channel. Muscle Nerve (Wiley Subscription Services, Inc, A Wiley Company). 2006;34:292\u20137.","journal-title":"Muscle Nerve (Wiley Subscription Services, Inc, A Wiley Company)"},{"key":"313_CR29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(76)91340-4","volume":"1","author":"P Wang","year":"1976","unstructured":"Wang P, Clausen T. Treatment of attacks in hyperkalaemic familial periodic paralysis by inhalation of salbutamol. Lancet. 1976;1:221\u20133.","journal-title":"Lancet"},{"key":"313_CR30","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1136\/jnnp.65.2.248","volume":"65","author":"MG Hanna","year":"1998","unstructured":"Hanna MG, Stewart J, Schapira AH, et al. Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A). J Neurol Neurosurg Psychiatry. 1998;65:248\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"313_CR31","doi-asserted-by":"crossref","unstructured":"Sansone V, Meola G, Links TP, et al. Treatment for periodic paralysis. Cochrane Database Syst Rev (Chichester, UK: John Wiley & Sons, Ltd) 2008;CD005045.","DOI":"10.1002\/14651858.CD005045.pub2"},{"key":"313_CR32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/1531-8249(200001)47:1<46::AID-ANA9>3.0.CO;2-H","volume":"47","author":"R Tawil","year":"2000","unstructured":"Tawil R, McDermott MP, Brown R, et al. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol. 2000;47:46\u201353.","journal-title":"Ann Neurol"},{"key":"313_CR33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.31.11.1423","volume":"31","author":"CF Torres","year":"1981","unstructured":"Torres CF, Griggs RC, Moxley RT, et al. Hypokalemic periodic paralysis exacerbated by acetazolamide. Neurology. 1981;31:1423\u20138.","journal-title":"Neurology"},{"key":"313_CR34","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/brain\/124.6.1091","volume":"124","author":"D Sternberg","year":"2001","unstructured":"Sternberg D, Maisonobe T, Jurkat-Rott K, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain. 2001;124:1091\u20139.","journal-title":"Brain"},{"key":"313_CR35","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1212\/01.WNL.0000143068.99794.5B","volume":"63","author":"SL Venance","year":"2004","unstructured":"Venance SL, Jurkat-Rott K, Lehmann-Horn F, et al. SCN4A-associated hypokalemic periodic paralysis merits a trial of acetazolamide. Neurology. 2004;63:1977.","journal-title":"Neurology"},{"key":"313_CR36","first-page":"182","volume":"6","author":"MC Dalakas","year":"1983","unstructured":"Dalakas MC, Engel WK. Treatment of \u201cpermanent\u201d muscle weakness in familial hypokalemic periodic paralysis. Muscle Nerve (Wiley Subscription Services, Inc, A Wiley Company). 1983;6:182\u20136.","journal-title":"Muscle Nerve (Wiley Subscription Services, Inc, A Wiley Company)"},{"key":"313_CR37","first-page":"18","volume":"6","author":"JO Levitt","year":"2008","unstructured":"Levitt JO. Practical aspects in the management of hypokalemic periodic paralysis. J Transl Med (BioMed Central Ltd). 2008;6:18.","journal-title":"J Transl Med (BioMed Central Ltd)"},{"key":"313_CR38","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3345\/kjp.2011.54.11.470","volume":"54","author":"J-Y Han","year":"2011","unstructured":"Han J-Y, Kim J-B. Familial hyperkalemic periodic paralysis caused by a de novo mutation in the sodium channel gene SCN4A. Korean J Pediatr. 2011;54:470\u20132.","journal-title":"Korean J Pediatr"},{"key":"313_CR39","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s00415-011-6204-9","volume":"259","author":"A Chaouch","year":"2012","unstructured":"Chaouch A, M\u00fcller JS, Guergueltcheva V, et al. A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome. J Neurol (Springer-Verlag). 2012;259:474\u201381.","journal-title":"J Neurol (Springer-Verlag)"},{"key":"313_CR40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.nmd.2011.10.009","volume":"22","author":"AG Engel","year":"2012","unstructured":"Engel AG. Current status of the congenital myasthenic syndromes. Neuromuscul Disord (Elsevier). 2012;22:99\u2013111.","journal-title":"Neuromuscul Disord (Elsevier)"},{"key":"313_CR41","first-page":"480","volume":"43","author":"CM Harper","year":"1998","unstructured":"Harper CM, Engel AG. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol (Wiley Subscription Services, Inc, A Wiley Company). 1998;43:480\u20134.","journal-title":"Ann Neurol (Wiley Subscription Services, Inc, A Wiley Company)"},{"key":"313_CR42","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.WNL.0000061483.11417.1B","volume":"60","author":"CM Harper","year":"2003","unstructured":"Harper CM, Fukodome T, Engel AG. Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology. 2003;60:1710\u20133.","journal-title":"Neurology"},{"key":"313_CR43","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.nmd.2011.08.002","volume":"22","author":"J Palace","year":"2012","unstructured":"Palace J, Lashley D, Bailey S, et al. Clinical features in a series of fast channel congenital myasthenia syndrome. Neuromuscul Disord (Elsevier BV). 2012;22:112\u20137.","journal-title":"Neuromuscul Disord (Elsevier BV)"},{"key":"313_CR44","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.nurt.2008.07.003","volume":"5","author":"U Schara","year":"2008","unstructured":"Schara U, Lochm\u00fcller H. Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics (Springer-Verlag). 2008;5:542\u20137.","journal-title":"Neurotherapeutics (Springer-Verlag)"},{"key":"313_CR45","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/jnnp.54.12.1069","volume":"54","author":"J Palace","year":"1991","unstructured":"Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry. 1991;54:1069\u201372.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"313_CR46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/eci.10.57","volume":"6","author":"PW Wirtz","year":"2010","unstructured":"Wirtz PW, Titulaer MJ, Gerven JMV, et al. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Immunol. 2010;6:867\u201374.","journal-title":"Expert Rev Clin Immunol"},{"key":"313_CR47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/mol.107.039867","volume":"73","author":"AC Errington","year":"2008","unstructured":"Errington AC, Stohr T, Heers C, et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol. 2008;73:157\u201369.","journal-title":"Mol Pharmacol"},{"key":"313_CR48","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1111\/j.1476-5381.2010.00976.x","volume":"161","author":"KM Kahlig","year":"2010","unstructured":"Kahlig KM, Lepist I, Leung K, et al. Ranolazine selectively blocks persistent current evoked by epilepsy-associated Na\u03bd1.1 mutations. Br J Pharmacol (Blackwell Publishing Ltd). 2010;161:1414\u201326.","journal-title":"Br J Pharmacol (Blackwell Publishing Ltd)"},{"key":"313_CR49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4161\/chan.2.6.7362","volume":"2","author":"S Rajamani","year":"2008","unstructured":"Rajamani S, Shryock JC, Belardinelli L. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na\u2009+\u2009channels by ranolazine. Channels (Austin). 2008;2:449\u201360.","journal-title":"Channels (Austin)"},{"key":"313_CR50","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.hrthm.2009.07.042","volume":"6","author":"S Rajamani","year":"2009","unstructured":"Rajamani S, El-Bizri N, Shryock JC, et al. Use-dependent block of cardiac late Na(+) current by ranolazine. Heart Rhythm. 2009;6:1625\u201331.","journal-title":"Heart Rhythm"},{"key":"313_CR51","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1124\/mol.107.041541","volume":"73","author":"GK Wang","year":"2008","unstructured":"Wang GK, Calderon J, Wang S-Y. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na\u2009+\u2009channel isoforms by ranolazine. Mol Pharmacol. 2008;73:940\u20138.","journal-title":"Mol Pharmacol"},{"key":"313_CR52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.expneurol.2014.02.023","volume":"255","author":"J-F Desaphy","year":"2014","unstructured":"Desaphy J-F, Carbonara R, Costanza T, et al. Preclinical evaluation of marketed sodium channel blockers in a rat model of myotonia discloses promising antimyotonic drugs. Exp Neurol. 2014;255:96\u2013102.","journal-title":"Exp Neurol"},{"key":"313_CR53","first-page":"3766","volume":"136","author":"F Wu","year":"2013","unstructured":"Wu F, Mi W, Cannon SC. Beneficial effects of bumetanide in a CaV1.1-R528H mouse model of hypokalaemic periodic paralysis. Brain (Oxford University Press). 2013;136:3766\u201374. This paper describes emerging experimental therapeutics in periodic paralysis.","journal-title":"Brain (Oxford University Press)"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0313-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-014-0313-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-014-0313-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T18:24:26Z","timestamp":1565720666000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-014-0313-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,15]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["313"],"URL":"https:\/\/doi.org\/10.1007\/s11940-014-0313-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,15]]},"article-number":"313"}}